Across TCGA pan-cancer cohorts, TRAJ38 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRAJ38 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TRAJ38 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAJ38 expression acts as an unfavorable survival marker.
SKCM are the cancer types where TRAJ38 Mutation most reproducibly stratifies survival.